Evidence map›Paper›PMID 41944191›Full record

ArticleJournal of neurochemistry2026

Clinical Evaluation of Three KRS Families and Cellular Analysis of Distinct ATP13A2 Mutations Reveal Different Levels of Iron Accumulation.

Ezgi Erterek, Benan Temizci, Şeyma Tekgül, Bilal Çakır, A Nazlı Başak, Murat Gültekin, Zuhal Yapıcı, Arzu Karabay

Abstract read
In one paragraph

Article in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ezgi ErterekMolecular Biology-Genetics and Biotechnology, Graduate School, Istanbul Technical University, Istanbul, Turkey.ORCID https://orcid.org/0009-0008-6216-3768
Benan TemizciDepartment of Molecular Biology and Genetics, Istanbul Technical University, Istanbul, Turkey.ORCID https://orcid.org/0000-0002-1872-941X
Şeyma TekgülResearch Center for Translational Medicine, Neurodegeneration Research Laboratory, Suna and Inan Kıraç Foundation, Koç University School of Medicine, Istanbul, Turkey.
Bilal ÇakırFood and Agricultural Research Center, Istanbul Sabahattin Zaim University, Istanbul, Turkey.ORCID https://orcid.org/0000-0003-2168-3667
A Nazlı BaşakResearch Center for Translational Medicine, Neurodegeneration Research Laboratory, Suna and Inan Kıraç Foundation, Koç University School of Medicine, Istanbul, Turkey.
Murat GültekinDepartment of Neurology, Erciyes University Faculty of Medicine, Kayseri, Turkey.
Zuhal YapıcıDepartment of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Arzu KarabayMolecular Biology-Genetics and Biotechnology, Graduate School, Istanbul Technical University, Istanbul, Turkey.ORCID https://orcid.org/0000-0001-5150-5349

Funding

Bilimsel Araştırma Projeleri Birimi, İstanbul Teknik Üniversitesi TYL-2021-43140Türkiye Sağlık Enstitüleri Başkanlığı 28599
6 · The paper itself

Abstract

Kufor-Rakeb Syndrome (KRS) is a rare neurodegenerative disease caused by homozygous mutations in the ATP13A2 gene. The ATP13A2 protein, found in lysosomal and late-endosomal membranes, performs cellular functions such as iron-chelating agent transport and intracellular iron homeostasis. Mutations in ATP13A2 can lead to intracellular iron accumulation; however, whether KRS caused by an ATP13A2 mutation falls under Neurodegeneration with Brain Iron Accumulation disorders has long been debated. The most fundamental reason is that magnetic resonance imaging (MRI) cannot identify iron deposits in the basal ganglia in all KRS cases. We hypothesize that analyzing iron deposition at the cellular level could be more sensitive in detecting varying levels of iron accumulation associated with different ATP13A2 mutations, and it may be more useful when conventional MRI fails to detect iron, yields inconclusive results, or cannot be performed. We identified two new ATP13A2 mutations (p.Leu518_Thr519del, and p.Leu939Pro) in this study and comparatively investigated the impacts of three distinct ATP13A2 mutations (p.Pro474fs, p.Leu518_Thr519del, and p.Leu939Pro) using KRS patients' primary fibroblasts and MCF7 cells overexpressing these mutated ATP13A2 proteins to analyze if these different mutations of ATP13A2 can cause differing levels of iron accumulation. Following the detection of iron deposits via Prussian blue staining and inductively coupled plasma mass spectrometry, the cell viability was assessed via MTT assay to ascertain the impact of iron accumulation. Each type of ATP13A2 mutation led to iron accumulation; however, frameshift and deletion mutations resulted in more iron accumulation than the missense mutation. In addition, the transient overexpression of the wild-type ATP13A2 attenuated the cell death caused by iron accumulation. This study demonstrated that different types of ATP13A2 mutations are related to varying levels of iron accumulation and provided an explanation for the inconsistent perspectives on the association of KRS with iron accumulation.

Indexed as

IronMutationProton-Translocating ATPasesFemaleFibroblastsHumansMaleParkinsonian DisordersATP13A2 protein, humanIronProton-Translocating ATPasesATP13A2ironKufor‐Rakeb syndromeNBIAnovel mutationParkinson's disease

Identifiers

PMID41944191
PMCPMC13054781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.